Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Prevnar

Known as: Prevenar 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
BackgroundSepsis is one of the main reasons for non-elective admission to pediatric intensive care units (PICUs), but little is… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2010
Highly Cited
2010
Background: Pneumococcal conjugate vaccine (PCV) was introduced in the United Kingdom immunization schedule in September 2006… Expand
Review
2007
Review
2007
Pre-licensure trials in Finnish and US infants demonstrated that PREVENAR was associated, respectively, with a 6% (95% CI, -4% to… Expand
Review
2007
Review
2007
Prevnar (heptavalent pneumococcal conjugate vaccine; PCV7) provides protection against invasive pneumococcal disease (IPD) caused… Expand
Review
2007
Review
2007
The 7-valent pneumococcal conjugate vaccine, Prevenar, was first licensed in the United States in 2000 for the prevention of… Expand
Highly Cited
2005
Highly Cited
2005
Aims: Prospective study to evaluate the impact of the 7-valent pneumococcal conjugate vaccine (Prevenar) on the nasopharyngeal… Expand
2003
2003
Resume Les affections invasives a pneumocoque representent actuellement une cause majeure de mortalite par maladie infectieuse… Expand
Review
2002
Review
2002
A new conjugate 7-valent vaccine to prevent pneumococcal infection (Prevenar, Wyeth) has recently received a European licence for… Expand
Review
2002
Review
2002
UNLABELLED PNCRM7 (Prevnar) is a pneumococcal vaccine containing seven capsular polysaccharide antigens from the bacterium… Expand
Highly Cited
2000
Highly Cited
2000
Heptavalent pneumococcal conjugate vaccine (PCV7) is recommended for universal use in children 23 months and younger, to be given… Expand
  • table 1
  • table 2
  • table 3